HQ Science is ushering in a new era of point-of-care, patient-centric, and decentralised personalised diagnostics with our innovative Tachyon platform. Successfully developed and validated for radiation protection applications, Tachyon now transforms clinical oncology by delivering real-time, actionable insights tailored to each patient’s unique molecular profile. This breakthrough enhances treatment accuracy and responsiveness, empowering clinicians to provide truly personalised care.
For professionals in clinical oncology, health protection, and molecular biology, Tachyon offers a proven solution to optimise patient outcomes and streamline diagnostic workflows. Its decentralised model brings advanced diagnostics closer to patients, while its robust validation and adaptability make it a valuable asset across diverse applications.
Tachyon is a portable, point-of-care molecular diagnostic device designed to provide actionable insights during large-scale radiation incidents. By integrating nanopore sequencing technology with advanced algorithms for real-time bioinformatics analysis and biological dose assessment, Tachyon enables rapid and accurate evaluation of an individual’s radiation exposure status.
Traditional biodosimetry methods, such as the dicentric chromosome assay, are time-consuming and resource-intensive — often requiring at least 96 hours to yield results and specialised laboratory facilities. In emergency scenarios where swift triage and treatment decisions are crucial, these methods are impractical. Tachyon addresses this critical need by offering a fast, efficient, and portable solution that leverages gene-expression-based biodosimetry. Capable of delivering results within 10 to 60 minutes, Tachyon significantly reduces the time required for dose assessment. This innovative approach enhances global health security by providing a reliable tool for managing radiation emergencies, enabling immediate decision-making, and improving clinical outcomes during critical situations.
Building on the capabilities of Tachyon, we are advancing into the field of infectious diseases to provide clinicians with rapid, point-of-care diagnostics. Our platform enables swift analysis of the host immune response, supporting accurate predictions of clinical outcomes. By detecting pathogens directly within patient samples, Tachyon reduces identification times, allowing for timely interventions. It also offers significant potential for antimicrobial resistance diagnostics, assisting healthcare professionals in managing resistant infections effectively. This expansion of Tachyon’s applications reflects our commitment to enhancing patient care through precise and adaptable technology.